New immunotherapy combination for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer (SCLC) that has not been treated before
- Your cancer was confirmed by a biopsy or cell sample, not just imaging
- You have at least one tumor that can be measured on scans
- You are generally healthy enough for chemotherapy (ECOG score 0–1, meaning you can do most daily activities)
- Your heart, liver, and kidney function are adequate for the treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests a combination of four treatments—a new immunotherapy drug, an anti-cancer medication, chemotherapy, and targeted radiation—for people with extensive-stage small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests a new combination of two drugs (sintilimab and anlotinib) for people with extensive-stage small cell lung cancer that has gotten worse after prior immunotherapy. The goal is to see if this combination can help control the cancer.
This trial tests a new drug called ZL-1310, alone or with other treatments, for people with small cell lung cancer that has spread (extensive-stage). It aims to see if ZL-1310 can help shrink tumors or slow the disease.
This trial tests adding a new immunotherapy drug (tarlatamab) to the standard first-line chemo-immunotherapy for extensive-stage small cell lung cancer. It aims to see if the combination works better than the usual treatment alone.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.